AI-driven genomic analysis firm SeqOne has agreed a deal to acquire Congenica, a Cambridge-based company spun out of the prestigious Wellcome Sanger Institute, for an undisclosed amount.
The acquisition ‘creates the largest global software pure player in the genomics space’, serving over 160 labs in more than 30 countries.
Founded in 2012, Congenica services over 25 private and public labs, including multiple NHS Genomics Laboratory Hubs and prestigious national programs such as Genomics England and the Hong Kong Genomic Program.
Meanwhile, France-based SeqOne has created a platform which provides clinical decision-support tools that enable molecular laboratories to deliver fast, accurate and scalable analysis of genetic data for applications in oncology, rare and inherited diseases and infectious diseases.
The acquisition pairs SeqOne’s AI-powered platform for Next-Generation Sequencing (NGS) analysis with Congenica’s trusted clinical decision support technology and clinical interpretation services.
The integrated offering will aim to turn complex genomic data into rapid, actionable insights in an attempt to speed up diagnosis for families affected by rare diseases.
It will also look to enable more precise and personalised cancer therapies.
“The rapid pace of personalized medicine demands continuous investment in software innovation and deep specialization,” said Martin Dubuc, CEO of SeqOne.
“By integrating Congenica’s world-class team, we are further enhancing our strong growth trajectory and ability to provide market-leading software to customers, expert interpretation services and deepening our presence in the UK market – a global leader in clinical genomics since the landmark 100,000 Genomes Project.”
The acquisition comes on the heels of a period of growth for SeqOne, which has seen the company double its revenue and expand its international presence from three to over 30 countries in just 12 months.
It also follows the successful acquisition of Life & Soft in April, which expanded the company’s capabilities into multi-omics and virology.
This, alongside the MedTech’s recent €20m funding round, has enabled it to carry out its strategy to build the definitive software operating system for the clinical genomics revolution.
The combined entity will serve over 160 customer laboratories in more than 30 countries, have a dedicated team of over 125 employees and enable over 200,000 patient genomic analyses in 2025 – a threefold increase on 2024.
Dr Andy Richards CBE, chairman of Congenica, added: “The board of Congenica is proud of the immense impact our technology has had on healthcare since our inception.
“We support this combination with SeqOne, believing their vision and resources are best positioned to carry that legacy forward and ensure our innovative platform continues to thrive and serve patients globally.”